

PUBBLICAZIONI

Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, Cova A, Canese R, Jachetti E, Rossetti M, Huber V, Parmiani G, Generoso L, Santinami M, Borghi M, Fais S, Bellone M, Rivoltini L. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. *Cancer Res.* 2012 Jun 1;72(11):2746-56. doi: 10.1158/0008-5472.CAN-11-1272. Epub 2012 May 16. PMID: 22593198

Filipazzi P, Bürdek M, Villa A, Rivoltini L, Huber V. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. *Semin Cancer Biol.* 2012 Aug;22(4):342-9. doi: 10.1016/j.semcancer.2012.02.005. Epub 2012 Feb 19. Review. PMID: 22369922

Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): An open-label, single-arm phase 2 trial. *Lancet Oncol.* 2012 Sep;13(9):879-86. doi: 10.1016/S1470-2045(12)70324-8. Epub 2012 Aug 13. PMID: 22894884

Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. *Clin Cancer Res.* 2012 Dec 1;18(23):6485-96. doi: 10.1158/1078-0432.CCR-12-1516. Epub 2012 Oct 2. PMID: 23032742

Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, Chiarion Sileni V, Tragni G, Santinami M, Vergani B, Villa A, Berti E, Umansky L, Beckhove P, Umansky V, Parmiani G, Rivoltini L, Castelli C. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: Impact on the antigen-specific T cell response. *Cancer Immunol Immunother.* 2013 May;62(5):897-908. doi: 10.1007/s00262-013-1397-7. Epub 2013 Apr 16. PMID: 23589107

Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Del Maschio A, Gianolli L, Fazio F, Marchianò A, Di Florio A, Maio M, Salomoni M, Gallo Stampino C, Del Fiacco M, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. *Int J Cancer.* 2013 Jun 1;132(11):2557-66. doi: 10.1002/ijc.27939. Epub 2012 Dec 13. PMID: 23151995

Vallacchi V, Vergani E, Camisaschi C, Deho P, Cabras AD, Sensi M, De Cecco L, Bassani N, Ambrogio F, Carbone A, Crippa F, Vergani B, Frati P, Arienti F, Patuzzo R, Villa A, Biganzoli E, Canevari S, Santinami M, Castelli C, Rivoltini L, Rodolfo M. Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30+ T lymphocytes with progression. *Cancer Res.* 2014 Jan 1;74(1):130-40. doi: 10.1158/0008-5472.CAN-13-1672. PMID: 24395820

Pos Z, Spivey TL, Liu H, Sommariva M, Chen J, Wunderlich JR, Parisi G, Tomei S, Ayotte BD, Stroncek DF, Malek JA, Robbins PF, Rivoltini L, Maio M, Chouchane L, Wang E, Marincola FM. Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology. *J Invest Dermatol.* 2014 May;134(5):1389-96. doi: 10.1038/jid.2013.495. Epub 2013 Nov 22. PMID: 24270663

Camisaschi C, De Filippo A, Beretta V, Vergani B, Villa A, Vergani E, Santinami M, Cabras AD, Arienti F, Triebel F, Rodolfo M, Rivoltini L, Castelli C. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: Involvement of LAG-3. *J Invest Dermatol*. 2014 Jul;134(7):1893-902. doi: 10.1038/jid.2014.29. Epub 2014 Jan 17. PMID: 24441096

Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, Fiore M, Gronchi A, Stacchiotti S, Casali PG, Pilotti S, Rivoltini L, Castelli C. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. *Br J Cancer*. 2014 Sep 23;111(7):1350-62. doi: 10.1038/bjc.2014.437. Epub 2014 Aug 7. PMID: 25101565

Castelli C, Rivoltini L, Rodolfo M, Tazzari M, Belgiovine C, Allavena P. Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. *Cancer Immunol Immunother*. 2015 Jan;64(1):83-9. doi: 10.1007/s00262-014-1576-1. Epub 2014 Jul 4. Review. PMID: 24993564

Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E, Villa A, Santinami M, De Braud F, Rivoltini L, Rodolfo M. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. *Oncotarget*. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599. PMID: 26684239

Rivoltini L, Chiodoni C, Squarcina P, Tortoreto M, Villa A, Vergani B, Burdek M, Botti L, Arioli I, Cova A, Mauri G, Vergani E, Bianchi B, Della Mina P, Cantone L, Bollati V, Zaffaroni N, Gianni AM, Colombo MP, Huber V. TNF-related apoptosis-inducing ligand (trail)-armed exosomes deliver proapoptotic signals to tumor site. *Clin Cancer Res*. 2016 Jul 15;22(14):3499-512. doi: 10.1158/1078-0432.CCR-15-2170. Epub 2016 Mar 4. PMID: 26944067

Tuccitto A, Tazzari M, Beretta V, Rini F, Miranda C, Greco A, Santinami M, Patuzzo R, Vergani B, Villa A, Manenti G, Cleris L, Giardiello D, Alison M, Rivoltini L, Castelli C, Perego M. Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells. *Stem Cells*. 2016 Oct;34(10):2449-2460. doi: 10.1002/stem.2413. Epub 2016 Jun 28. PMID: 27301067

Gutzmer R, Rivoltini L, Levchenko E, Testori A, Utikal J, Ascierto PA, Demidov L, Grob JJ, Ridolfi R, Schadendorf D, Queirolo P, Santoro A, Loquai C, Dreno B, Hauschild A, Schultz E, Lesimple TP, Vanhouette N, Salaun B, Gillet M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF. Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. *ESMO Open*. 2016 Aug 8;1(4):e000068. eCollection 2016. PMID: 27843625

Bossi P, Bergamini C, Miceli R, Cova A, Orlandi E, Resteghini C, Locati L, Alfieri S, Imbimbo M, Granata R, Mariani L, Iacovelli NA, Huber V, Cavallo A, Licitra L, Rivoltini L. Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2016 Dec 1;96(5):959-966. doi: 10.1016/j.ijrobp.2016.08.047. Epub 2016 Sep 6. PMID: 27745982

Huber V, Camisaschi C, Berzi A, Ferro S, Lugini L, Triulzi T, Tuccitto A, Tagliabue E, Castelli C, Rivoltini L. *Sem. Cancer Biol*. 2017 Apr;43:74-89. doi: 10.1016/j.semcancer.2017.03.001. REpub 2017 Mar 6. Review. PMID: 28267587

Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, Gronchi A, Astolfi A, Pantaleo MA, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. *Journal of Investigative Dermatology* 2017 Feb;137(2):484-493. doi: 10.1016/j.jid.2016.06.634. Epub 2016 Sep 5. PMID: 27608549